Hottest Stocks
(Over $10)
Hottest Stocks
($2-$10)
Biggest Losers
(Over $10)
Biggest Losers
($2-$10)
Hottest
Industries
Hottest
Sectors
EPS / Sales
Surprises
 
Enter Ticker Symbol:   Ticker Lookup
 

Enter any portion of the company’s name to find its corresponding ticker symbol:
Search for :   

Zacks Company Profile for Aligos Therapeutics, Inc. (ALGS : NSDQ)
 
 • Company Description   
Aligos Therapeutics, Inc. is a clinical stage biopharmaceutical company. It is focused on the development of antiviral therapies for chronic hepatitis B and coronaviruses as well as liver diseases. Aligos Therapeutics, Inc. is based in SAN FRANCISCO, Calif.

Number of Employees: 70

 
 • Price / Volume Information   
Yesterday's Closing Price: $7.84 Daily Weekly Monthly
20 Day Moving Average: 121,849 shares
Shares Outstanding: 6.11 (millions)
Market Capitalization: $47.94 (millions)
Beta: 2.77
52 Week High: $46.80
52 Week Low: $3.76
Short Interest Ratio:
  % Price Change % Price Change Relative to S&P 500
4 Week 29.59% 22.57%
12 Week 96.49% 64.85%
Year To Date -80.32% -81.57%
 
 • Address & Contact Information
Street Address Phone / Fax Email Address Web URL
ONE CORPORATE DR. 2ND FLOOR
-
SOUTH SAN FRANCISCO,CA 94080
USA
ph: 800-466-6059
fax: -
jtarazi@aligos.com http://www.aligos.com
 
 • General Corporate Information   
Officers
Lawrence M. Blatt - Chairman; President; and Chief Executive Officer
Lesley Ann Calhoun - Executive Vice President; Chief Operating Officer
K. Peter Hirth - Director
James Scopa - Director
Margarita Chavez - Director

Peer Information
Aligos Therapeutics, Inc. (CORR.)
Aligos Therapeutics, Inc. (RSPI)
Aligos Therapeutics, Inc. (CGXP)
Aligos Therapeutics, Inc. (BGEN)
Aligos Therapeutics, Inc. (GTBP)
Aligos Therapeutics, Inc. (RGRX)
Industry / Sector / Ticker Info
Analyst Coverage: No
Industry Group: MED-BIOMED/GENE
Sector: Medical
CUSIP: 01626L204
SIC: 2836
Fiscal Year
Fiscal Year End: December
Last Reported Quarter: 03/01/25
Next Expected EPS Date: 08/05/25
Share - Related Items
Shares Outstanding: 6.11
Most Recent Split Date: 8.00 (0.04:1)
Beta: 2.77
Market Capitalization: $47.94 (millions)
 
 
 • EPS Information     • Dividend Information
Analyst Coverage: No Dividend Yield: 0.00%
Current Fiscal Quarter EPS Consensus Estimate: $-2.47 Indicated Annual Dividend: $0.00
Current Fiscal Year EPS Consensus Estimate: $-9.71 Payout Ratio:
Number of Estimates in the Fiscal Year Consensus: 2.00 Change In Payout Ratio:
Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00
Next EPS Report Date: 08/05/25  
 

 • Fundamental Ratios
P/E
Current FY Estimate: -
Trailing 12 Months: -
PEG Ratio: -
Price Ratios
Price/Book: 0.41
Price/Cash Flow: -
Price / Sales: 14.66
EPS Growth
vs. Year Ago Period: 61.64%
vs. Previous Quarter: 38.12%
Sales Growth
vs. Year Ago Period: -68.46%
vs. Previous Quarter: -50.56%
ROE
06/30/25 - -
03/31/25 - 14.67
12/31/24 - -190.19
ROA
06/30/25 - -
03/31/25 - 7.19
12/31/24 - -71.29
Current Ratio
06/30/25 - -
03/31/25 - 7.56
12/31/24 - 2.86
Quick Ratio
06/30/25 - -
03/31/25 - 7.56
12/31/24 - 2.86
Operating Margin
06/30/25 - -
03/31/25 - 229.73
12/31/24 - -1,785.53
Net Margin
06/30/25 - -
03/31/25 - -1,628.75
12/31/24 - -3,326.01
Pre-Tax Margin
06/30/25 - -
03/31/25 - -1,618.04
12/31/24 - -3,317.62
Book Value
06/30/25 - -
03/31/25 - 19.05
12/31/24 - -7.50
Inventory Turnover
06/30/25 - -
03/31/25 - -
12/31/24 - -
Debt-to-Equity
06/30/25 - -
03/31/25 - 0.00
12/31/24 - -
Debt-to-Capital
06/30/25 - -
03/31/25 - 0.10
12/31/24 - -
 

Powered by Zacks Investment Research ©